This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Hydrotalcite is an antacid indicated in the treatment of heartburn and excess gastric acid.

Generic Name
Hydrotalcite
DrugBank Accession Number
DB13322
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental, Investigational
Structure
Weight
Average: 619.973
Monoisotopic: 617.940176
Chemical Formula
CH24Al2Mg6O24
Synonyms
  • Hydrotalcite

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetaminophenHydrotalcite can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineHydrotalcite can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.
AlfacalcidolThe serum concentration of Hydrotalcite can be increased when it is combined with Alfacalcidol.
AlimemazineHydrotalcite can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolThe therapeutic efficacy of Allopurinol can be decreased when used in combination with Hydrotalcite.
AmiodaroneThe risk or severity of hypotension can be increased when Hydrotalcite is combined with Amiodarone.
AmlodipineThe risk or severity of hypotension can be increased when Hydrotalcite is combined with Amlodipine.
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Hydrotalcite.
AmprenavirHydrotalcite can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SWECON SUSPENSION 100MG/MLSuspension100 MG/MLOralY.S.P. INDUSTRIES (M) SDN BHD2020-09-08Not applicableMalaysia flag
SWECON TABLETTabletOralY.S.P. INDUSTRIES (M) SDN BHD2020-09-08Not applicableMalaysia flag

Categories

ATC Codes
A02AD04 — Hydrotalcite
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic oxides / Organic aluminium salts / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
Substituents
Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic aluminium salt / Organic cation / Organic oxide / Organic oxygen compound / Organic salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
17432CG1KU
CAS number
12304-65-3
InChI Key
BEBILBPAQKONJS-UHFFFAOYSA-L
InChI
InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2
IUPAC Name
dialuminium(3+) ion hexamagnesium(2+) ion dodecahydrate carbonate nonaoxidandiide
SMILES
O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O

References

General References
  1. DIMDI Drug Product Information: Talidat (hydrotalcite) chewable tablets [Link]
ChemSpider
32698917
RxNav
27221
Wikipedia
Hydrotalcite

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentDyspepsia1
4CompletedTreatmentHeartburn1
4Not Yet RecruitingTreatmentNSAIDs-associated Intestinal Mucosal Injury1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, liquid filledOral500 mg
Tablet, chewableOral1000 MG
Powder
Tablet, chewableOral
Tablet, chewableOral500 mg
Suspension
Tablet, chewableOral
SuspensionOral100 MG/ML
TabletOral
Tablet, chewableBuccal1000 mg
SuspensionOral1000 mg
SuspensionOral
Tablet, chewableBuccal500 mg
TabletOral500 mg
SuspensionOral10 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility51.2 mg/mLALOGPS
logP1.84ALOGPS
logP0.25Chemaxon
logS-0.93ALOGPS
pKa (Strongest Acidic)6.05Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area63.19 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity31.17 m3·mol-1Chemaxon
Polarizability3.52 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04